News Focus
News Focus
Followers 23
Posts 2804
Boards Moderated 0
Alias Born 03/22/2021

Re: Doc logic post# 795595

Thursday, 10/30/2025 2:20:47 PM

Thursday, October 30, 2025 2:20:47 PM

Post# of 822801
A question doc, do you think BP believes it will be cheaper to partner with NWBO rather than a B/O? I don't understand how Merck has not bought them out considering they only have keytruda monopoly for 2 more years.

"Keytruda profits for merck this year 2025
Merck's Keytruda has been a significant contributor to the company's profits in 2025. The drug's sales reached $8.14 billion, marking a 10% increase from the previous year. This performance has been attributed to strong demand for Keytruda as a treatment for various cancers. Merck's full-year adjusted earnings for 2025 are expected to range between $8.93 and $8.98 per share, reflecting the company's strategy to offset revenue losses from the upcoming patent expiration of Keytruda in 2028."

When LP talks about a franchise, do you think she means NWBO will be the only company to allow dc-vax/ keytruda combo after 2028? Is LP playing the 2 year long game?

Interesting to see yesterdays dilution being absorbed by the market.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News